Methods of Improving Stem Cell Homing and Engraftment
AssigneeGamida Cell Ltd.
InventorTony Peled
Life of this patent
Estimating the term…
Abstract
A method of enhancing cell engraftment potential is provided. The method comprising ex-vivo or in-vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient to effect the population of cells, thereby enhancing cell engraftment potential.
Claims59
A method of enhancing cell homing and engraftment potential, the method comprising ex-vivo or in vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient for enhancing cell homing and engraftment potential, the method further characterized by at least one of the following:
- (i) wherein said population of cells is a hematopoietic stem and/or progenitor cell population, and said period of time is selected insufficient for stem cell expansion, or under conditions insufficient for stem and/or progenitor cell expansion;
- (ii) wherein said amount of nicotinamide and said period of time are selected sufficient to down regulate CD26 expression by cells of said population of cells but not for stem and/or progenitor cell expansion;
- (iii) said population of cells does not include hematopoietic cells, hematopoietic stem cells, mononuclear cells, early liver progenitor cells, committed progenitor cells, non-hematopoietic stem and progenitor cells, or embryonic stem and progenitor cells;
- (iv) said subjecting is in the absence of nutrients;
- (v) said subjecting is in the absence of a cytokine;
- (vi) said subjecting is in the absence of FLT-3 ligand;
- (vii) said subjecting is in the absence of stem cell factor (SCF);
- (viii) said subjecting is in the absence of granulocyte colony stimulating factor (GCSF);
- (ix) said subjecting is in the absence of an early acting cytokine;
- and
- (x) said subjecting is in the absence of a late acting cytokine.
A method of transplanting cells in a subject, the method comprising:
- (a) ex-vivo subjecting a population of cells comprising the cells to an amount of nicotinamide for a period of time sufficient to enhance homing and engraftment in said cells;
- the method further characterized by at least one of the following:
- (i) wherein said population of cells is a hematopoietic stem and/or progenitor cell population, and said period of time is selected insufficient for stem cell expansion, or under conditions insufficient for stem and/or progenitor cell expansion;
- (ii) wherein said amount of nicotinamide and said period of time are selected sufficient to down regulate CD26 expression by cells of said population of cells but not for stem and/or progenitor cell expansion;
- (iii) said population of cells does not include hematopoietic cells, hematopoietic stem cells, mononuclear cells, early liver progenitor cells, committed progenitor cells, non-hematopoietic stem and progenitor cells, or embryonic stem and progenitor cells;
- (iv) said subjecting is in the absence of nutrients;
- (v) said subjecting is in the absence of a cytokine;
- (vi) said subjecting is in the absence of FLT-3 ligand;
- (vii) said subjecting is in the absence of stem cell factor (SCF);
- (viii) said subjecting is in the absence of granulocyte colony stimulating factor (GCSF);
- (ix) said subjecting is in the absence of an early acting cytokine;
- (x) said subjecting is in the absence of a late acting cytokine;
- and subsequently
- (b) transplanting the cells in a subject in need thereof.
Dependencies are inferred from the claim text.